Sonographic and cyst fluid cytological changes after EUS-guided pancreatic cyst ablation by Kim, Kook Hyun et al.
Accepted Manuscript
Sonographic and cyst fluid cytological changes after EUS-guided pancreatic cyst
ablation
Kook Hyun Kim, MD, Kathleen McGreevy, RN, Kristin La Fortune, MD, Harvey
Cramer, MD, John DeWitt, M.D, FASGE, FACG
PII: S0016-5107(16)30580-6
DOI: 10.1016/j.gie.2016.09.011
Reference: YMGE 10239
To appear in: Gastrointestinal Endoscopy
Received Date: 1 June 2016
Accepted Date: 8 September 2016
Please cite this article as: Kim KH, McGreevy K, La Fortune K, Cramer H, DeWitt J, Sonographic and
cyst fluid cytological changes after EUS-guided pancreatic cyst ablation, Gastrointestinal Endoscopy
(2016), doi: 10.1016/j.gie.2016.09.011.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Sonographic and cyst fluid cytological changes after EUS-guided pancreatic 
cyst ablation 
 
Kook Hyun Kim MD1,2, Kathleen McGreevy RN1, Kristin La Fortune MD 3 
Harvey Cramer MD 3, John DeWitt M.D, FASGE, FACG1 
 
1Division of Gastroenterology and Hepatology, Indiana University School of Medicine University 
Hospital, Indianapolis, IN, 
2Division of Gastroenterology and Hepatology, Department of Internal medicine, Yeungnam University 
College of Medicine, Daegu, Republic of Korea 
3Department of Cytopathology and Laboratory Medicine, Indiana University School of Medicine 
University Hospital, Indianapolis, IN 
 
Running Title: Sonographic and cytological changes following EUS-FNA 
 
Correspondence to: John DeWitt, M.D. 
 Division of Gastroenterology/Hepatology, Indiana University School of Medicine 
 University Hospital, Room 4100, 550 University Blvd. Indianapolis, IN 46202-5149 
 Phone: (317) 944-1113 
 Fax: (317) 274-8145 
 E-mail: jodewitt@iupui.edu 
 
Disclosure: All authors disclosed no financial relationships relevant to this publication. 
 
Author contributions: John DeWitt designed the research and reviewed the paper; Kook Hyun Kim 
analyzed the data, performed the study, and wrote the paper; Kathleen McGreevy collected the data;
Kristin La Fortune and Harvey Cramer retrieved and reviewed slides.  

M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Abstract  
 
Background and Aims: The effect of EUS-guided pancreatic cyst ablation (PCA) on sonographic 
morphology and cyst fluid cytology is unknown. The aim of this study is to evaluate morphological, 
cytological and change in cyst fluid DNA after PCA.  
 
Methods: In a prospective single center study, consecutive patients with suspected benign 10 to 50 
mm pancreatic cysts underwent baseline EUS-FNA and EUS-PCA followed 2 to 3 months later by 
repeat EUS, cyst fluid analysis and possible repeat PCA. Surveillance imaging after ablation was 
performed at least annually and classified as complete (CR), partial (PR), or persistent with <5%, 5% 
to 25%, and 25% of the original cyst volume, respectively. 
 
Results: 36 patients underwent EUS-PCA with ethanol alone (n = 8) or ethanol and paclitaxel (n = 28) 
and CR occurred in 19 (56%). After EUS-PCA, EUS showed an increase in wall diameter in 68%, 
decreased number of septations in 24%, increased debris in 24%, loss of mural nodule or novel 
calcification in 21%, and alteration of fluid viscosity in 48%. Follow-up cytology showed increased 
epithelial cellularity in 27%, loss or decreased cellular atypia in 15%, and increased or appearance of 
macrophages in 24% and inflammatory cells in 15%. Post-ablation DNA amount increased and quality 
decreased in 71% each. Between the CR and non-CR patients, there was no significant difference in 
frequency of sonographic or cytological features. In the CR group, mean DNA quantity was 
significantly increased after ablation (p=0.023) without a change in quality (p=0.136)  
 
Conclusions: EUS-PCA induces morphological and cytological changes of the pancreatic cysts none 
of which appear to predict overall imaging-defined response to ablation. 
 
 
 
 
INTRODUCTION 
 
Asymptomatic or symptomatic pancreatic cystic lesions (PCLs) are frequently diagnosed with the 
widespread of cross-sectional diagnostic modalities such as computed tomography (CT) or magnetic 
resonance imaging (MRI). These cysts range from inflammatory (pseudocyst) or benign (serous cyst 
adenoma, SCA) lesions to premalignant (mucinous cystic neoplasm [MCN] or intraductal papillary 
mucinous neoplasm [IPMN]) or malignant cysts. The management of pancreatic cysts is principally 
based on accurate identification of related symptoms and malignant potential. Symptomatic or 
premalignant cysts often require surgical resection, yet surgical resection or enucleation is associated 
with high perioperative morbidity (20% to 40%) and mortality rate (~ 2%).1-5 Therefore, EUS-guided 
pancreatic cyst ablation (EUS-PCA) with ethanol and/or paclitaxel has been investigated for non-
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operative treatment of PCLs in patients potentially at high risk for or averse to surgery.6, 7 Cyst ablation 
with ethanol and paclitaxel leads to a complete (<5% of original cyst volume) or partial (5%-25% of 
original cyst volume) image-defined response in 60%-70% of patients and may lead to elimination of 
baseline cyst fluid DNA mutations.6, 7 However, the effect of ablation on cyst sonographic morphology, 
cyst fluid cytology and the quality and quantity of cyst fluid DNA is unknown. The primary aim of this 
single center prospective study was to evaluate changes of cyst fluid cytology and sonographic 
morphology after EUS-PCA with ethanol lavage alone or combined with paclitaxel injection. The 
secondary aim was to evaluate the qualitative and quantitative alteration of DNA after ablation.  
 
PATIENTS AND METHODS 
 
Study population 
This is a single-center prospective study on consecutive patients who underwent pancreatic cyst 
ablation at Indiana University Health Hospital over a 10-year period. This study was approved by the 
Institutional Review Board at Indiana University Health Hospital, and all patients signed informed 
consent before enrollment (Clinical-Trials.gov identifiers NCT00233038 and NCT01643460). Patients 
considered for ablation were at least 18 years of age and referred for evaluation of a pancreatic cyst 
detected by previous cross-sectional imaging that measured 10 to 50 mm in diameter and contained 5 
or fewer septations. Most patients treated had cysts that met criteria for surgical resection yet surgery 
was either refused by the patient or the patient was regarded as unfit for surgery by the referring 
physician or surgeon.8 Cysts were not considered for treatment if any of the following criteria were 
present: pregnancy, high risk for respiratory failure due to deep sedation with propofol (American 
Society of Anesthesiology class IV or V), acute pancreatitis and pancreatic necrosis, ascites, portal 
hypertension, suspicious malignancy including pancreatic cancer, and coagulopathy (international 
normalized ratio >1.5, activated partial thromboplastin time >50 seconds, platelet count <50,000/µL, 
use of antiplatelet medications or anticoagulants that could not be discontinued). 
 
Study design   
Baseline demographics, symptoms and radiographic data were recorded in all patients. Before 
ablation, EUS morphology (i.e. septations, cyst wall thickness, presence of nodules) and maximal 2-
dimension cross-sectional diameter were recorded. Cyst fluid aspiration was then performed and the 
quantity, viscosity and color of fluid were documented. The sample was sent for cytology in all patients 
and carcinoembryonic antigen (CEA) and molecular analysis (RedPath Integrated Technologies) in 
selected patients. Patients underwent initial ablation with saline solution or ethanol alone (as part of a 
randomized trial) from 2004 to 20099 or ethanol plus paclitaxel (in a prospective cohort study)7 from 
2009 to 2014. After index ablation, all patients underwent follow-up EUS 2 to 3 months later for 
assessment of any interval changes in sonographic morphology of the treated cyst. During this first 
follow-up EUS during the years 2004 to 2009, diagnostic EUS was followed by FNA for cytology and 
finally an index or second ethanol lavage (depending on initial randomization). For patients treated 
initially with ethanol and paclitaxel from 2009 to 2014, the first follow-up EUS consisted of diagnostic 
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EUS, repeat EUS-FNA for cytology in all patients and molecular analysis (when possible) and finally 
repeat cyst ablation in patients with an initial suboptimal response. In all patients (regardless of initial 
ablation regimen), repeat CT, MRI, or EUS was performed 3 to 6 months later and then annually to 
assess for size change from ablation or possible recurrence. Repeat EUS-FNA in previously ablated 
cysts was performed on a case-by-case basis. All 3-dimensional CT or MR images for baseline and 
follow-up assessment were interpreted by a single radiologist. 
 
Cyst fluid aspiration and lavage process 
Details regarding the process of cyst ablation have been described elsewhere.7, 9 Briefly, a curvilinear-
array echoendoscope (Olympus GF-UC140P-AL5; Olympus America Inc., Center Valley, Pa, USA) 
was used to puncture the cyst via transgastric or transduodenal route using a single pass of a 22-
gauge needle (EchoTip Ultra; Cook Endoscopy Inc., Winston-Salem, North Carolina; or Expect, 
Boston Scientific America, Natick, Mass, USA). After near total collapse of the cyst, 100% ethanol was 
injected though needle into the cyst using the same volume as that initially aspirated. After lavage of 
the cyst contents repeatedly for 3 to 5 minutes, the lesion was nearly completely drained of fluid in all 
patients. After 2009, with the needle still within the cyst, paclitaxel (Bedford Laboratories, Bedford, 
Ohio, USA) at a concentration of 2 mg/mL (supplied as 6mg/ mL and diluted 1:2 with normal saline 
solution) was injected into the cyst (using a volume equal to that initially aspirated from the cyst) and 
left in place. 
 
Cytology slide evaluation 
Cytology slides from all baseline and post-ablation FNA specimens were prepared by both an air-dried 
modified Diff-Quik stain and a wet-fixed modified Pap stain. Slides were retrieved and reviewed for 
each patient in random order by a single, blinded cytopathologist for the amount (none, few, moderate, 
excessive) of mucin, inflammatory cells, macrophages, amount (acellular, hypocellular, cellular) and 
atypia (none, mild to moderate, severe) of epithelial cells and cellular debris in the entire slide sample. 
When more than one post-ablation sample was obtained, only the first sample obtained after ablation 
was compared to the baseline sample.   
 
Study definitions 
Baseline and post-ablation cyst volume were evaluated by 2-dimensional (linear EUS) or 3-
dimensional (CT or MRI) measurements. Two-dimensional cyst volume was measured using the 
formula 4/3πr3, where r represents radius of the maximal cyst by linear EUS image. Three-
dimensional volume was calculated by the simplified formula d1×d2×d3/2, where d1, d2, and d3 
represent the maximal diameters in the axial, coronal, and sagittal planes, respectively.10 Changes in 
cyst size measured by axial CT or MRI after ablation were defined as complete response (CR), partial 
response (PR), or persistent with <5%, 5% to 25%, and >25% of the original cyst volume, 
respectively.6, 9 Cysts were classified according to available information including cyst fluid analysis 
(cytology, amylase, CEA, baseline DNA data, and viscosity) and the presence of communication with 
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the main pancreatic duct. Viscosity was classified as thin, slightly viscous and highly viscous based on 
visual inspection of both the fluid aspirated in the syringe and fluid expressed on the microscope slide 
during in-room cytology preparation. In current study, cyst fluid CEA >192ng/mL was considered to be 
an MCN or IPMN and when analyzed, a cyst fluid amylase >800U/L was considered suggestive of 
IPMNs or pseudocysts.11, 12 Both cyst fluid CEA < 192ng/mL and cyst fluid amylase < 800U/L was 
suggestive of a serous cystic neoplasm.13 If cyst fluid analysis was not compatible with these criteria, 
a clinical diagnosis was rendered based on the available information. Adverse events were classified 
according to the published criteria.14  
 
Cyst fluid DNA mutational analysis 
 
Molecular analyses were performed by laboratory personnel who were blinded to clinical and 
management features as well as any prior molecular analysis on an individual patient. DNA was 
extracted from 200 µL of pancreatic cyst fluid (Qiagen, Valencia, Calif, USA) and quantified by 
ultraviolet-visible spectrophotometry (NanoDrop, Willmington, Del, USA). DNA amplifiability was then 
determined by quantitative polymerase chain reaction (PCR; iCycler; BioRad, Hercules, Calif, USA).15, 
16
 Cycle threshold is measured in DNA quality (a parameter of degree of DNA strand degradation) and 
is measured and quantified by PCR on the DNA with primers. The critical cycle threshold (Ct) value 
means a critical point, number of cycle where the DNA suddenly becomes visible. If Ct value is ≤27.5, 
it is categorized as good quality DNA, however, if Ct value >27.5, poor quality DNA. Optical density 
(OD) was used as a measure of DNA quantity at 260/280 wavelength.  
 
Statistical analysis  
EUS morphological and cytological changes before and after PCA were evaluated and results were 
compared between CR and non-CR (PR and persistent) patients. Continuous variables were 
described as means ± standard deviation. The Fisher exact test and linear by linear association were 
used to compare categorical parameters between the 2 groups (CR vs non-CR). The Wilcoxon signed 
rank test was applied for nonparametric statistics regarding DNA analysis (DNA quantity and quality) 
between baseline and post-ablation. Differences with a P value less than 0.05 were considered 
statistically significant. Statistical analysis was performed using SPSS version 16 (SPSS, Inc., 
Chicago, Ill, USA) 
 
RESULTS 
 
Baseline characteristics and study algorithm 
Between October 2004 and July 2015, 36 patients (mean age 69.1 ± 12.2 years, 24 female) 
underwent cyst ablation. Baseline demographics, symptom, imaging and clinical diagnosis are 
summarized in Table 1. Of the 36 patients, 22 (61.1%) cysts were found in the body and tail. Median 
follow-up (time from initial EUS-PCA to final CT, MRI, or EUS) was 22.3 months (range 3.0-119.9).
The mean original 3-dimensional CT or MRI and 2-dimensional EUS cyst volume were 10.1 ± 10.3 mL 
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(range 0.5-38.3) and 12.1 ± 11.2 mL (range 0.5-41.6), respectively. Eleven (30.6%) patients were 
symptomatic before treatment. Median cyst fluid CEA (n=33) and amylase (n=27) were 444 ng/mL 
(range 0-156,600) and 162 U/L (range 5-327,297), respectively. Presumed clinical diagnosis were 16 
(44.4%) MCN, 14 (38.9%) branched IPMN, 5 (13.9%) SCA and 1 pseudocyst. The schematic 
algorithm for cyst ablation and genetic evaluation of the pancreatic cyst fluid is illustrated in Figure 1 
and Figure 2. 
 
Pancreatic cyst ablation and adverse events 
Of the 36 patients, EUS-PCA was performed with ethanol alone in 8 (22%) and a combined ethanol 
lavage with paclitaxel injection in 28 (78%) (Fig. 1). A second and third ablation were performed in 17 
(47%) and 1 (3%), respectively. Repeat ablation was not performed in remaining 18 (50%) patients 
(Fig. 1) due to acute pancreatitis (n=3), decreased cyst size (n=11), decreased cyst size with 
increased internal debris (n=1), pseudocyst formation at gastric wall (n=1), markedly increased 
internal debris (n=1) and refusal (n=1) after the first ablation. Except for 2 patients who did not receive 
follow-up 3-dimensional cross-sectional imaging (CT or MRI), follow-up imaging study in 34 (94%) 
demonstrated amedian volume change of -97% (range -100% to +220%) compared with baseline
(Fig. 3). By study definition, a complete response, partial response and non-response were achieved 
in 19 out of 34 (56%), 7 (21%) and 8 (23%), respectively. Including follow-up examinations, a total of 
54 ablations were performed with 9 (17%) procedure-related adverse events including abdominal pain 
in 4 (7%), pancreatitis in 4 (7%) and intracystic hemorrhage in 1 (2%). All 4 patients with pancreatitis 
required hospitalization for 6 to 8 days and were discharged without further interventions.    
 
Sonographic change and cytological change after ablation 
Post-ablation EUS examinations were performed in 34 patients with follow-up cross-sectional imaging. 
The development of any sonographic alterations between baseline and any post-ablation 
examinations are shown in Table 2. After EUS-PCA, follow-up EUS showed an increase in cyst wall 
diameter in 23 out of 34 (68%) (Fig. 4A, B). Eight (24%) patients had decreased number (n=3, 9%) or 
loss of septations (n = 5, 15%) (Fig. 5A-D) whereas more septations were noted in 2 (6%). Intracystic 
debris developed in 8 (24%) (Fig. 6A, B). After ablation, there was a disappearance of mural nodule in 
5 (15%), development of novel mural calcification in 1 (3%), and both mural nodule loss and 
development of calcification in 1 (3%) (Fig. 7A-C). No difference in sonographic changes was present 
between complete responders compared to those with a partial or no response. Similar results were 
obtained when comparing the persistent group to the CR + PR groups. 
Cytological changes between pre-ablation and post-ablation specimens in 34 patients are 
summarized in Table 3. Median interval between baseline and first post-ablation cytology was 3.3 
months (range 1.9-30.1). Twenty-four patients had 1 specimen whereas 10 had 2 or more. Follow-up 
cytology after PCA showed overall increased epithelial cellularity in 9/34 (27%). Cellular atypia after 
ablation was eliminated or decreased in 5 (15%) and increased or newly developed in 3 (9%). 
Microscopically, an increase of debris was observed in 12 (36%), and an increase or new appearance 
of macrophages in 8 (24%) and inflammatory cells in 5 (15%). Grossly, there was alteration of cyst 
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fluid viscosity in 14 (48.3%) after ablation. No difference in cytological changes was present between 
complete responders compared to those with a partial or non-response. Similar results were obtained 
when comparing the persistent group to the CR + PR groups, except viscosity change (p=0.013).  
 
Molecular DNA analysis  
Baseline, pre-ablation cyst fluid DNA evaluation in 20 patients who underwent ablation with ethanol 
and paclitaxel analysis (Fig. 2) showed a mean DNA quantity (OD) and quality (Ct value) of 60.4 ± 
239.6 ng/uL (range 1.6-1,078.0) and 29.3 ± 2.8 (range 24.3-36.8), respectively. In three, post-ablation 
DNA analysis was not available because of failed amplification (n=1), 1 patient who refused the test 
(n=1) and in 1 who was lost follow-up (n=1). For the remaining 17 patients, mean post-ablation DNA 
quantity and quality were 35.8 ± 60.6 ng/uL (range 1.5-255.4) and 27.1 ± 2.9 (range 23.8-32.9), 
respectively. When classified by imaging response, post-ablation DNA amount increased in 12 out of 
17 (70.6%), including 10 of 12 (83.3%) in the CR group, whereas overall post-ablation DNA Ct value 
decreased in 12 of 17 (70.6%) patients, including 9 of 12 (75%) in the CR group. For the CR group, 
mean DNA quantity was significantly increased after ablation (44.8 ± 70.7 vs 6.7 ± 9.5, p=0.023), but 
no change in quality (p=0.136) (Table 4).  
 
DISCUSSION 
 
EUS-PCA with ethanol alone or in combination with paclitaxel has emerged as a safe and feasible 
alternative to surgery in the management of benign cystic lesions.6, 9, 17 Previous studies have 
evaluated response to ablation principally by results of cross-sectional imaging or surgery performed 
after ablation.6, 9, 17 However, the sonographic and cytological changes after pancreatic cyst ablation 
have not been evaluated. 
In the current study, we found that ablation was associated with an increase in cyst wall diameter in 
68% of patients. We hypothesize this increase results from epithelial denuding, fibrosis and chronic 
inflammation of the wall that has been reported in patients undergoing surgery after pancreatic cyst 
ablation.6, 9 It is likely that an ablative agent may activate unknown mediators that cause an 
inflammatory response and resultant damage to the epithelial lining cells of cystic wall.18-20 Histological 
examination of surgical specimens of thyroid nodules after percutaneous ethanol injection also 
showed irreversible fibrous change, hemorrhage, and granulation tissue formation in the central 
lesion.21, 22 The observed cytological changes in the cyst fluid in a minority of patients after ablation 
(increased cellularity, inflammatory cells, macrophages) have also been described after ablation of 
hepatic and thyroid cysts and likely reflect cystic wall destruction.23, 24 The plausible cellular 
mechanism likely reflects a cascade of inflammation induced by the ablative agent which changes 
cellular elements of the cyst by mobilizing inflammatory cells and macrophages.20, 23  
Additional sonographic changes noted included a decreased number or loss of septations in 39%, 
increased internal debris in 24% and loss of mural nodule loss or calcification in 21%. Increased 
intracystic debris may be a combination of lysed blood cells, sloughed lining cells, contaminated cells 
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and mucin from ablation of cyst epithelium.23, 24 Loss of visible nodules likely results of destruction of 
mucin adherent to the cyst wall and less likely treatment of an epithelial nodule. The treatment of 
septated cysts were first reported by Oh et al.25 These authors postulated that the loss or decreasing 
numbers of the ablated septae may be affected by the number of needle punctures, thickness of 
septae, and the size of locules. Interestingly, nine patients in our study showed increased numbers of 
septae after ablation. The reasons for this finding are not clear but may reflect a post-inflammatory 
response to ablation. We found no differences in the frequency of sonographic or cytological features 
assessed between patients with a complete and incomplete response to ablation.  
We found that pancreatic cyst ablation increased the quantity and decreased the quality of cyst fluid 
DNA sampled after ablation with ethanol combined with paclitaxel. Furthermore, there was a 
significant increase of the OD value in CR group without any difference in observed Ct. These findings 
may reflect epithelial cell turnover after ablation. However it is also possible that the observed 
changes may reflect one or both ablative agents alone or the release of DNA from the influx of 
inflammatory cells or blood lysates in the ablated cyst fluid. The observed alterations in DNA quality 
and quantity may support a previous observation that mutant cyst fluid DNA may be eliminated with 
pancreatic cyst ablation.7 
Abdominal pain, pancreatitis, and intracystic hemorrhage are most important adverse events related 
to the cyst ablation. A series of previous studies have reported that overall procedure-related adverse 
events have included pancreatitis ranging from 3% to 10% and abdominal pain in up to 13% of 
patients, which concurs with this study.7, 9, 17, 25, 26 In 54 ablations, procedure–related adverse events 
included abdominal pain (7%), pancreatitis (7%) and intracystic hemorrhage (2%). In particular, a total 
of 4 pancreatitis patients had full recovery without further interventions and no case of serious 
adverse events such as venous obliteration or thrombosis occurred in this study.26  
The current study is the first to describe sonographic and cytological changes after pancreatic cyst 
ablation. Furthermore, pathology slides and most cross sectional radiographs were reviewed by a 
single cytopathologist and radiologist, respectively. However, our study has several limitations. First, 2 
different ablative regimens were used for the study population and may have led to different outcomes. 
Second, DNA changes were only observed for patients treated with ethanol and paclitaxel. Therefore, 
the effect of ablation with ethanol alone on cyst fluid DNA cannot be assessed. Third, the sample 
sizes are limited with only 34 patients with follow-up imaging and 17 with post ablation molecular DNA 
analysis. A final limitation of this study is that surgical or histological samples of the treated cysts were 
not obtained because most patients responded to endoscopic treatment alone.  
In conclusion, EUS-PCA induces morphological and cytological changes of the pancreatic cysts which 
appear to reflect ablation of cyst wall epithelium. However, none of which appear to predict overall 
imaging-defined response to ablation. 
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Legends of figures 
Figure 1. Study profile for EUS guided ablation for pancreatic benign cysts  
EUS, endoscopic ultrasound 
 
Figure 2. Profile for DNA analysis before and after pancreatic cyst ablation in 20 patients  
*Neither follow-up CT nor DNA analysis in this patient was done. EUS, endoscopic ultrasound  
 
Figure 3. Percent change in cyst volume in 32 patients with follow-up imaging after pancreatic cyst 
ablation 
 
Figure 4. 
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A, Linear EUS in a 54-year-old woman, demonstrating a single 24mm X 20mm cyst with thin cystic 
wall measured ~1mm in the head/neck junction of the pancreas. The clinical diagnosis was mucinous 
cystic neoplasm. The patient underwent an ethanol lavage combined with paclitaxel. B, A follow-up 
EUS 3 months later demonstrated a single 15mm X 8mm cyst. The outer wall of the lesion was 
homogenously thickened measuring 3.5mm. 
 
Figure 5.  
A, Linear EUS in a 77-year-old woman, demonstrating a 32mm X 20mm cyst in maximal cross-
sectional diameter with multiple, thin septa in the body/tail of the pancreas. The clinical diagnosis was 
branched intraductal papillary mucinous neoplasm. B, The largest locule downstream measuring 
19mm X 16mm (arrows) was treated with an ethanol lavage combined with paclitaxel using a 22 
gauge needle. C, A follow-up EUS 3 month later demonstrated that an 11mm X 8mm downstream cyst 
previous treated was smaller than previous study. Another 14mm X 11mm upstream (arrows) was 
ablated with same regimen. D, A follow-up EUS 14 month later demonstrated a 5mm X 5mm cyst at 
body. 
 
Figure 6.  
A, Linear EUS in a 65-year-old woman, demonstrating a single 18mm X 10mm cyst without internal 
debris within the fluid-filled cavity in the body of the pancreas. The clinical diagnosis was branched 
intraductal papillary mucinous neoplasm. The patient underwent an ethanol lavage combined with 
paclitaxel. B, A follow-up EUS scan 4 month later demonstrated a single 14mm X 11mm cyst. The 
outer wall of the lesion was thick and there was abundant internal debris (arrows) within the fluid-
filled cystic cavity most likely representing necrosis. Therefore, no additional ablation was performed 
due to nearly complete internal necrosis. SA, splenic artery 
 
Figure 7.  
A, Linear EUS in a 64-year-old woman, demonstrating a 26mm X 18mm nonseptated cyst in the 
uncinate pancreas. A mural nodule (arrow) measuring 5mm X 6mm was present along the medial 
wall of the cyst. The clinical diagnosis was IPMN. The patient underwent an ethanol lavage combined 
with paclitaxel. B, A follow-up linear EUS 3 month later demonstrated a 16mm X 10mm cyst with thick 
wall measuring 2.4mm. There was a mural nodule (arrow) within the cyst measuring 3mm X 3mm. 
Second ablation was done by the same regimen. C, A follow-up radial EUS 9 months later 
demonstrated an 11mm X 8mm cyst with disappearance of mural nodule. 

 
 
 
 
 
 
TABLE 1. Baseline demographics and imaging characteristics of 36 patients with pancreatic 
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cysts treated with ethanol and/or paclitaxel 
   
The values are presented as mean ± SD, median (range) or numbers (%). IPMN, intraductal papillary 
mucinous neoplasm; MCN, mucinous cyst neoplasm; SCA, serous cyst adenoma; PC, pseudocyst. 
 
 
 
TABLE 2. Sonographic change of pancreatic cysts after EUS-guided pancreatic cyst ablation in 
Variables Results (n=36) 
Age (years)  
  
Mean ± SD 
69.1 ± 12.2 
Gender  
  Female 
 
24 (67) 
ASA class  
  I 
  II 
  III 
 
3 (8.3) 
26 (72.2)  
7 (19.4) 
Location  
Body, tail  
Head, neck, uncinate 
22 (61.1) 
14 (38.9) 
Symptomatic cyst  11(31) 
Follow-up duration (months) 
  Median (range) 
 
22.3 (3.0-119.9) 
CT volume (mL) 
  Mean ± SD 
  Range 
 
10.10±10.29  
0.50-38.26 
EUS maximal diameter (mm) 
  Mean ± SD 
  Range  
 
25.8 ± 8.7 
10-43 
  Volume (mL)  12.07 ± 11.20 (0.52-41.63)  
Cystic fluid CEA (ng/mL)  
  Median (range) 444 (0-156,600) 
Cystic fluid Amylase (Units/L)  
  Median (range) 162 (5-327,297) 
Presumed diagnosis   
  Branched IPMN 14 (38.9) 
  MCN 16 (44.4) 
  SCA 5 (13.9) 
  PC 1 (2.8) 
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34 patients 


Sonographic change CT response* 
 Total 
(n=34) 
CR1 
(n=19) 
Non-CR1 
(n=15) 
P value 
Wall thickness  
Increase 
Decrease or no change 
 
23 (67.6) 
11 (32.4) 
 
14 (73.7) 
5 (26.3) 
 
9 (60.0) 
6 (40.0) 
 
0.316 
Septations  
Decrease or loss† 
Increase  
None 
 
8 (23.5)2 
2 (5.9) 
24 (70.6) 
 
4 (21.1) 
1 (5.3) 
14 (73.7) 
 
4 (26.7) 
1 (6.7) 
10 (66.7) 
 
0.660 
 
Internal debris  
 Increase or newly formed 
 Loss  
 None  
 
8 (23.5) 
2 (5.9) 
24 (70.6) 
 
3 (15.8) 
1 (5.3) 
15 (78.9) 
 
5 (33.3) 
1 (6.7) 
9 (60.0) 
 
0.236 
Mural nodule  
Loss or calcification‡ 
Persistent  
None 
 
7 (20.6) 
4 (11.8) 
23 (67.6) 
 
3 (15.8) 
1 (5.3) 
15 (78.9) 
 
4 (26.7) 
3 (20.0) 
8(53.3) 
 
0.119 

The values are presented as number (%). 
*Two cases were not shown because follow-up CT was not performed. CT response was defined as 
CR (complete response) and non-CR if cyst size after ablation is <5% or ≥5% of the original cyst 
volume, respectively. 
†Of 8 patients, there were decreased numbers of septations (n= 3) and loss of septations (n= 5) 
‡Of two calcifications, one patient had loss of mural nodule and novel calcification, another one had 
appearance of calcification.  
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TABLE 3. Cytological change of pancreatic cysts after EUS-guided pancreatic cyst ablation in 
34 patients 
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Cytological change CT response* 
 Total  
(n=34) 
CR  
(n=19) 
Non-CR 
 (n=15) 
P value 
Cellularity of cyst epithelium  
  Increase 
  Decrease 
  No change 
 
9 (26.5) 
9 (26.5) 
16 (47.1) 
 
7 (36.8) 
4 (21.1) 
8 (42.1) 
 
2 (13.3) 
5 (33.3) 
8 (53.3) 
 
0.234 
Cyst epithelium atypia† 
Newly develop 
Loss 
None 
 
3 (8.8) 
5 (14.7) 
26 (76.5) 
 
2 (10.5) 
3 (15.8) 
14 (73.7) 
 
1 (6.7) 
2 (13.3) 
12 (80.0) 
 
0.644 
 
 
Internal debris  
Increase or develop 
Decrease or loss 
None 
 
12 (35.3) 
6 (17.6) 
16 (47.1) 
 
7 (36.8) 
2 (10.5) 
10 (52.6) 
 
5 (33.3) 
4 (26.7) 
6 (40.0) 
 
0.772 
Macrophages  
  Increase or develop 
  Decrease or loss 
  None 
 
8 (23.5) 
5 (14.7) 
21 (61.8) 
 
4 (21.1) 
2 (10.5) 
13 (68.4) 
 
4 (26.7) 
3 (20.0) 
8 (53.3) 
 
0.482 
Inflammatory cells  
  Increase or develop 
  Decrease or loss 
None 
 
5 (14.7) 
3 (8.8) 
26 (76.5) 
 
3 (15.8) 
0 
16 (84.2) 
 
2 (13.3) 
3 (20.0) 
10 (66.7) 
 
0.555 
Viscosity of cyst fluid  
 Increase 
Decrease 
No change 
 
5 (17.3) 
9 (31.0) 
15 (51.7) 
 
1 (6.2) 
6 (37.5) 
9 (56.2) 
 
4 (30.8) 
3 (23.1) 
6 (46.2) 
 
0.228 
 
 
 
The values are presented as number (%). 
*Two cases were not shown because follow-up CT was not performed. CT response was defined as 
CR (complete response) and non-CR if cyst size after ablation <5% and ≥5% of the original cyst 
volume, respectively. 
†All cases were mild atypia 
 
 
 
 
 
 
 
 
 
TABLE 4. The change of cyst fluid DNA quantity and quality after EUS-guided pancreatic cyst 
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ablation in 20 patients. 
 
 
 
*One case was not shown here because both follow-up CT and post-ablation DNA were not 
performed. Complete: if CT volume reduction ≥ - 95%; Partial: -75 ~ - 95%; persistent: < -75% 
†OD is measure of DNA amounts at 260/280 wavelength 
‡Postablation DNA analysis was not available (1 partial response, 1 persistent) 
§Cyclic threshold (Ct) is a measure of DNA quality and amplifiability 
¶P value is calculated by Wilcoxon signed rank test 
 
 
 
 
 
 
 
 
 
8CTKCDNG %6TGURQPUG*
 &RPSOHWH  Q  3DUWLDOQ   3HUVLVWHQWQ 
DNA quantity (OD)†, mean  SD, ng/µL      
     Baseline  
      Post Ablation     
     P value¶ 
 
6.7±9.5   
44.8±70.7  
0.023 
 
540.8±759.8  
14.4 
 
8.8±6.6  
13.8±11.8  
- 0.715 
Change of DNA quantity after ablation (n, %)            
      Increase 10 (83.3) 0 2 (40.0) 
       Decrease 2 (16.7) 1  2 (40.0) 
       n/a‡ - n/a  n/a 
DNA quality, mean ± SD, Ct value§    
       Baseline    29.4±2.2 (25.9-34.0) 26.9±3.7 (24.3-29.5) 30.3±4.0 (25.8-36.8) 
       Post ablation  26.8±3.0 (24-33) 31.0 27.5±2.1 (25-30) 
       P value¶ 0.136  0.273 
Change of DNA Ct value after ablation (n, %)             
Increase 3 (25.0) 1 (50.0) 1 (20.0) 
      Decrease 9 (75.0) 0 3 (60.0) 
     n/a‡ - n/a n/a 
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$EEUHYLDWLRQ 
(86 HQGRVFRSLF XOWUDVRXQG 3&$ SDQFUHDWLF F\VW DEODWLRQ 3&/ SDQFUHDWLF F\VWLF OHVLRQ &7
FRPSXWHGWRPRJUDSK\05,PDJQHWLFUHVRQDQFHLPDJLQJ(863&$(86JXLGHGSDQFUHDWLFF\VW
DEODWLRQ (W2+ HWKDQRO 37; 3DFOLWD[HO 6&$ VHURXV F\VW DGHQRPD 0&1 PXFLQRXV F\VWLF
QHRSODVP ,301 LQWUDGXFWDO SDSLOODU\ PXFLQRXV QHRSODVP &($ FDUFLQRHPEU\RQLF DQWLJHQ &5
FRPSOHWHUHVSRQVH35SDUWLDOUHVSRQVH3&5SRO\PHUDVHFKDLQUHDFWLRQ&WF\FOHWKUHVKROG2'
RSWLFDOGHQVLW\

